Literature DB >> 1738084

HIV-1 and HIV-2 seroprevalence rates in mother-child pairs living in The Gambia (west Africa).

A Del Mistro1, J Chotard, A J Hall, H Whittle, A De Rossi, L Chieco-Bianchi.   

Abstract

A seroepidemiological study was conducted, during 1988 and 1989, of mother-child pairs living in The Gambia (West Africa) in order to determine the distribution of the human immunodeficiency viruses type 1 (HIV-1) and type 2 (HIV-2). Specimens were obtained from 931 children (age range, 14-17, months) and 923 mothers (age range, 14-17 years) using village-based cluster samples; the children are participating in The Gambia Hepatitis Intervention Study (GHIS), a large-scale HBV vaccination program. Large numbers of indeterminate Western blot patterns were observed among the mothers, mainly for HIV-1 antibodies; HIV-1 infected subjects were not found, whereas an HIV-2 seroprevalence rate of 0.75% was observed. The children born to the seven HIV-2 positive women were seronegative for HIV-2 antibodies, and none of the children showed HIV-2 or HIV-1 seropositively.

Entities:  

Mesh:

Year:  1992        PMID: 1738084

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  3 in total

1.  Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter.

Authors:  M A Montano; C P Nixon; M Essex
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Retrospective study of maternal HIV-1 and HIV-2 infections and child survival in Abidjan, Côte d'Ivoire.

Authors:  K M De Cock; F Zadi; G Adjorlolo; M O Diallo; M Sassan-Morokro; E Ekpini; T Sibailly; R Doorly; V Batter; K Brattegaard
Journal:  BMJ       Date:  1994-02-12

3.  Epidemiology of HIV-2 infection in Spain. The HIV-2 Spanish Study Group.

Authors:  V Soriano; M Gutiérrez; E Caballero; G Cilla; J L Fernández; A Aguilera; C Tuset; F Dronda; A M Martín; E Carballo; I López; J González-Lahoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.